<DOC>
	<DOCNO>NCT00299338</DOCNO>
	<brief_summary>This Phase I/II non-randomized , open-label clinical study 8 week duration use SP01A HIV positive patient stable antiretroviral regimen . Dose response safety associate oral administration four dos ( 200 mg , 400 mg , 600 mg , 800 mg daily ) SP01A study total 24 study subject . In addition , six HIV-negative subject recruit control cortisol secretion receive study medication .</brief_summary>
	<brief_title>A Dose Response Safety Study Procaine HCl HIV-Infected Patients</brief_title>
	<detailed_description>STUDY PLAN : DESCRIPTION This investigation non-randomized , open-label study four dos SP01A 24 individual infect HIV treat triple combination antiretroviral therapy . Additionally , group six HIV-negative subject ( group E ) recruit control cortisol secretion . This group receive study medication evaluate dose response safety parameter . DISCUSSION OF STUDY DESIGN , INCLUDING CONTROL GROUP Patients receive follow dos SP01A divide low dose high dose group analyse . There two segment within low dose group . Group A receive 200 mg SP01A per day . Group B administer 200 mg SP01A twice daily . Similarly , two segment high dose group . Group C treat 200 mg SP01A three time per day , Group D administer 400 mg SP01A twice daily . A fifth group also introduce . This group , Group E , serve control group receive treatment . The study conduct single investigative center ( AIDS ReSearch Alliance , West Hollywood , CA ) . Six subject diagnosis HIV also receive triple combination antiretroviral therapy minimum 2 month plan per group . Patients admit in-patient facility 72 hour . After initial night acclimate patient facility , 24-hour measurement cortisol secretion blood urine conduct . After complete , patient receive initial single dose SP01A orally . ( 200 mg SP-01A group A , 400 mg group B , 600 mg group C , 800 mg group D ) . Blood urine sample also collect 24 hour evaluate safety study medication . Patients discharge facility . After 4-day washout , patient return facility start 8-week dose-response study , sequentially use four dos divide ( 200 mg daily group A , 200 mg twice day group B , 200 mg three time per day group C , 400 mg twice daily group D ) . Subjects return study center day screen close day week practical Weeks 1 ( baseline ) , 2 , 3 , 4 , 5 , 6 , 7 , 8 ( end treatment ) 10 ( post-treatment examination specimen collection , well evaluation reaction study treatment ) . At end 8-week drug administration period , patient admit in-patient facility 72 hour . As , patient initial night acclimate facility , follow 24-hour measurement cortisol secretion blood urine . In morning , follow end 24 hour basal cortisol secretion , patient four successive group ( A , B , C , D ) , receive last dose medication . They also give last blood urine sample next 24 hour additional safety sample collection . The total duration study subject participation 11 week . The six HIV negative subject enrol group E. After initial night acclimate facility , blood urine sample collect determine baseline 24 hour blood urine cortisol secretion . Patients discharge . No study medication give patient group E .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Procaine</mesh_term>
	<criteria>1 . Eighteen year age old ( male female ) . 2 . If female , agree use suitable contraception prevent pregnancy . 3 . HIV positive confirm viral load use nucleic acid sequence base amplification ( NASBA ) , enzymelinked immunosorbent assay ( ELISA ) Western Blot , cohort A , B , C , D. HIV negative ELISA Western blot cohort E. 4 . Karnofsky Performance Status score least 60 . 5 . No active opportunistic infection . Prophylaxis MAl , CMV , Pneumocystis Pneumonia except Bactrim ) , herpes permit . 6 . Current CD4 count &gt; 200 . 7 . Stable triple therapy antiretroviral regimen ( cohorts A , B , C , D ) precede 8 week willing make change regimen study . 8 . Not take unapproved experimental treatment HIV , include antiretrovirals immune modulators ( interferon interleukin ) . 9 . Capable willing provide inform consent . 10 . Agreed take Epoetin trial . 11 . Baseline laboratory value : Neutrophils &gt; 1000 cells/mm3 ; Platelets &gt; 75,000 cells/mL ; SGOT &lt; 3 time upper limit normal ; SGPT &lt; 3 time upper limit normal ; Creatinine &lt; 2.0 mg/dL . 1 . Known suspected allergy procaine hydrochloride . 2 . Patients take DHEA supplementation oral ketoconazole ( anticortisol property ) . 3 . Patients use sulfonamide ( include Septra/Bactrim ) . 4 . Required use sulfonamide , eg , Septra/Bactrim . ( Procaine hydrochloride may inactivate sulfonamide ) . 5 . Patients glaucoma use anticholinesterase inhibitor ( Humorsol [ demecarium bromide ] echothiophate iodide , Floropryl [ isoflurophate ] , IsoptoEserine [ physostigmine salicylate ] ) . Anticholinesterase Inhibitors use procaine hydrochloride , since procaine anticholinesterase activity . 6 . Patients less 6 month life expectancy . 7 . Patients adrenal insufficiency ( determined screen ACTH stimulation test ) . 8 . Patients lymphoma . 9 . Patients active hepatitis ( viral drug induce ) . 10 . Patients cancer , except peripheral Kaposi 's sarcoma . 11 . Patients dialysis . 12 . Patients pregnant . 13 . Female patient childbearing age use two form birth control abstain sexual intercourse trial . 14 . Any medical , psychological , psychiatric , substance use problem , opinion Principal Investigator , interfere patient 's ability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>CD4</keyword>
	<keyword>HAART</keyword>
	<keyword>antiretroviral</keyword>
	<keyword>treatment failure</keyword>
	<keyword>resistance</keyword>
	<keyword>CCR4</keyword>
	<keyword>CXCR5</keyword>
	<keyword>gp120</keyword>
	<keyword>gp41</keyword>
	<keyword>cholesterol</keyword>
	<keyword>lipid raft</keyword>
	<keyword>intracellular fluid</keyword>
	<keyword>receptor</keyword>
	<keyword>chemokine</keyword>
	<keyword>antigen</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>